Browse studies

Find your next paid study

9 recruiting studies matching your filters

ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome

ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to…

Dravet Syndrome

Estimated

~$10 – $8,750

Encoded TherapeuticsNCT05419492

Phase 3

A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX…

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients With Dravet Syndrome

The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).

Dravet Syndrome

Estimated

~$10 – $8,750

Ionis Pharmaceuticals, Inc.NCT07531745

Phase 3

EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.

Dravet Syndrome

Estimated

~$10 – $8,750

Stoke Therapeutics, IncNCT06872125

Phase 4

The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome (FAST-DS) Project.

This study investigates cerebrovascular reactivity (CVR) and functional brain connectivity in Dravet Syndrome (DS) patients with convulsive seizures. Using fun…

Dravet Syndrome

Estimated

~$10 – $6,250

The University of Texas Health Science Center, HoustonNCT07112365

Phase 4

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under the Age of 24 Months

Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children wit…

Dravet Syndrome (DS)Children Under 2 Years

Estimated

~$10 – $6,250

University of Colorado, DenverNCT06598449

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical resear…

Estimated

~$10 – $1,050

Sanguine BiosciencesNCT05635266

Phase 1

Preliminary Evaluation of the Safety and Efficacy of CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in Individuals Diagnosed with Dravet Syndrome And/or Lennox-Gastaut Syndrome

This study is a preliminary open-label, single-arm Phase II investigation into the safety and efficacy of transdermal cannabidiol (CBD) delivered using GT4 ski…

Lennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)

Estimated

~$10 – $7,500

Alexander RotenbergNCT06738732

Electrophysiological Biomarkers of GABA Metabolism in Children With SCN1A+ Dravet Syndrome

This study will non-invasively obtain levels of GABA in the brain of children with SCN1A+DS and neurodeveloping children through evoked and induced cortical re…

Dravet Syndrome

Estimated

~$10 – $1,125

Cook Children's Health Care SystemNCT05651204